Review of human infections with avian influenza H5N1 and proposed local clinical management guideline

Annals of the Academy of Medicine Singapore

Volumn 36, Issue 4, 2007, Pages 285-292

  Lye, David C B ^a   Ang, Brenda S P ^a   Leo, Yee Sin ^a  

^a TAN TOCK SENG HOSPITAL   (Singapore)

Author keywords

H5N1 subtype; Influenza A; Influenza in birds; Literature review

Indexed keywords

OSELTAMIVIR;

ADULT RESPIRATORY DISTRESS SYNDROME; AVIAN INFLUENZA; CAMBODIA; CLINICAL FEATURE; DISEASE TRANSMISSION; DRUG EFFICACY; HONG KONG; HUMAN; INFECTION; LABORATORY DIAGNOSIS; MEDLINE; MORTALITY; POULTRY FARMING; REVIEW; THAILAND; VIET NAM; VIRUS PNEUMONIA; VIRUS REPLICATION;

EID: 34548182796     PISSN: 03044602     EISSN: 29724066     Source Type: Journal    
DOI: None     Document Type: Review

References (40)

1. World Organisation for Animal Health (OIE). Update on Avian Influenza in Animals (type H5). Updated 23 February 2006. Available at: http://www.oie.int/ downld/AVIAN%20INFLUENZA/A_AI-Asia.htm. Accessed 27 February 2006.
2. Liem NT, Lim W; World Health Organisation International Avian Influenza Investigation Team, Vietnam. Lack of H5N1 avian influenza transmission to hospital employees, Hanoi, 2004. Emerg Infect Dis 2005;11:210-15.
3. World Health Organization. Epidemic and Pandemic Alert and Response (EPR): Avian Influenza. Updated 20 February 2006. Available at: http://www.who.int/csr/disease/avian_influenza/en/. Accessed 27 February 2006.
4. Nicholson KG, Wood JM, Zambon M. Influenza. Lancet 2003;362:1733-45.
5. Horimoto T, Kawaoka Y. Pandemic threat posed by avian influenza A viruses. Clin Microbiol Rev 2001;14:129-49.
6. Yuen KY, Wong SS. Human infection by avian influenza A H5N1. Hong Kong Med J 2005;11:189-99.
7. Ungchusak K, Auewarakul P, Dowell SF, Kitphati R, Auwanit W, Puthavathana P, et al. Probable person-to-person transmission of avian influenza A (H5N1). N Engl J Med 2005;352:333-40.
8. Yuen KY, Chan PK, Peiris M, Tsang DN, Que TL, Shortbridge KF, et al. Clinical features and rapid viral diagnosis of human disease associated with avian influenza A H5N1 virus. Lancet 1998;351:467-71.
9. Avian influenza: assessing the pandemic threat, January 2005. Available at: http://www.who.int/csr/disease/influenza/WHO_CDS_2005_29/en/index.html. Accessed 27 February 2006.
10. Cox NJ, Subbarao K. Influenza. Lancet 1999;354:1277-82.
11. Monto AS, Gravenstein S, Elliott M, Colopy M, Schweinle J. Clinical signs and symptoms predicting influenza infection. Arch Intern Med 2000;160:3243-7.
12. Beigel JH, Farrar J, Han AM, Hayden FG, Hyer R, de Jong MD, et al; Writing Committee of the World Health Organization Consultation on Human Influenza A/H5. Avian influenza A (H5N1) infection in humans. N Engl J Med 2005;353:1374-85. Erratum in: N Engl J Med 2005;354:884.
13. Katz JM, Lim W, Bridges CB, Rowe T, Hu-Primmer J, Lu X, et al. Antibody response in individuals infected with avian influenza A (H5N1) viruses and detection of anti-H5 antibody among household and social contacts. J Infect Dis 1999;180:1763-70.
14. Bridges CB, Katz JM, Seto WH, Chan PK, Tsang D, Ho W, et al. Risk of influenza A (H5N1) infection among health care workers exposed to patients with influenza A (H5N1), Hong Kong. J Infect Dis 2000;181:344-8.
15. Mounts AW, Kwong H, Izurieta HS, Ho Y, Au T, Lee M, et al. Case-control study of risk factors for avian influenza A (H5N1) disease, Hong Kong, 1997. J Infect Dis 1999;180:505-8.
16. Bridges CB, Lim W, Hu-Primmer J, Sims L, Fukuda K, Mak KH, et al. Risk of influenza A (H5N1) infection among poultry workers, Hong Kong, 1997-1998. J Infect Dis 2002;185:1005-10.
17. Schultsz C, Dong VC, Chau NV, Le NT, Lim W, Thanh TT, et al. Avian influenza H5N1 and healthcare workers. Emerg Infect Dis 2005;11:1158-59.
18. Chotpitayasunondh T, Ungchusak K, Hanshaoworakul W, Chunsuthiwat S, Sawanpanyalert P, Kijphati R, et al. Human disease from influenza A (H5N1), Thailand, 2004. Emerg Infect Dis 2005;11:201-9.
19. Apisarnthanarak A, Kitphati R, Thongphubeth K, Patoomanunt P, Anthanont P, Auwanit W, et al. Atypical avian influenza (H5N1). Emerg Infect Dis 2004;10:1321-4.
20. Tran TH, Nguyen TL, Nguyen TD, Luong TS, Pham PM, Nguyen VC, et al. Avian influenza A (H5N1) in 10 patients in Vietnam. N Engl J Med 2004;350:1179-88.
21. Thorson A, Petzold M, Nguyen TK, Ekdahl K. Is exposure to sick or dead poultry associated with flu-like illness? Arch Intern Med 2006;166:119-23.
22. Chan PK. Outbreak of avian influenza A (H5N1) virus infection in Hong Kong in 1997. Clin Infect Dis 2002;34 (Suppl 2):S58-S64.
23. Peiris JS, Yu WC, Leung CW, Cheung CY, Ng WF, Nicholls JM, et al. Re-emergence of fatal human influenza A subtype H5N1 disease. Lancet 2004;363:617-9.
24. Cheung CY, Poon LLM, Lau AS, Luk W, Lau YL, Shortbridge KF, et al. Induction of pro-inflammatory cytokines in human macrophages by influenza A (H5N1) viruses: a mechanism for the unusual severity of human disease? Lancet 2002;360:1831-7.
25. Guan Y, Poon LL, Cheung CY, Ellis TM, Lim W, Lipatov AS, et al. H5N1 influenza: a protean pandemic threat. Proc Natl Acad Sci USA 2004;101:8156-61.
26. Fritz RS, Hayden FG, Calfee DP, Cass LM, Peng AW, Alvord WG, et al. Nasal cytokine and chemokine responses in experimental influenza A virus infection: results of a placebo-controlled trial of intravenous zanamivir treatment. J Infect Dis 1999;180:586-93.
27. Playford EG, Dwyer DE. Laboratory diagnosis of influenza virus infection. Pathology 2002;34:115-25.
28. Rowe T, Abernathy RA, Hu-Primmer J, Thompson WW, Lu X, Lim W, et al. Detection of antibody to avian influenza A (H5N1) virus in human serum by using a combination of serologic assays. J Clin Microbiol 1999;37:937-43.
29. Gubareva LV, Kaiser L, Hayden FG. Influenza virus neuraminidase inhibitors. Lancet 2000;355:827-35.
30. Moscona A. Neuraminidase inhibitors for influenza. N Engl J Med 2005;353:1363-73.
31. Leneva IA, Goloubeva O, Fenton RJ, Tisdale M, Webster RG. Efficacy of zanamivir against avian influenza A viruses that possess genes encoding H5N1 internal proteins and are pathogenic in mammals. Antimicrob Agents Chemother 2001;45:1216-24.
32. Govorkova E, Leneva IA, Goloubeva OG, Bush K, Webster RG. Comparison of efficacies of RWJ-270201, zanamivir, and oseltamivir against H5N1, H9N2, and other avian influenza viruses. Antimicrob Agents Chemother 2001;45:2723-32.
33. Yen HL, Monto AS, Webster RG, Govorkova EA. Virulence may determine the necessary duration and dosage of oseltamivir treatment for highly pathogenic A/Vietnam/1203/04 influenza virus in mice. J Infect Dis 2005;192:665-72.
34. WHO interim guidelines on clinical management of humans infected by influenza A (H5N1), 20 February 2004. Available at: http://www.who.int/csr/ disease/avian_influenza/guidelines/clinicalmanage/en/index.html. Accessed 27 February 2006.
35. Aoki FY, Macleod MD, Paggiaro P, Carewicz O, El Sawy A, Wat C, et al. Early administration of oral oseltamivir increases the benefits of influenza treatment. J Antimicrob Chemoth 2003;51:123-9.
36. de Jong MD, Tran TT, Truong HK, Vo MH, Smith GJ, Nguyen VC, et al. Oseltamivir resistance during treatment of influenza A (H5N1) infection. N Engl J Med 2005;353:2667-72.
37. Moscona A. Oseltamivir-resistant influenza? Lancet 2004;364:733-4.
38. McKimm-Breschkin JL. Management of influenza virus infections with neuraminidase inhibitors: detection, incidence, and implications of drug resistance. Treat Respir Med 2005;4:107-16.
39. Bridges CB, Kuehnert MJ, Hall CB. Transmission of influenza: implications for control in health care settings. Clin Infect Dis 2003;37:1094-101.
40. Salgado CD, Farr BM, Hall KK, Hayden FG. Influenza in the acute hospital setting. Lancet Infect Dis 2002;2:145-55. Erratum in: Lancet Infect Dis 2002;2:383.